~ Buy the LUMAKRAS (sotorasib) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR LUMAKRAS

All Clinical Trials for LUMAKRAS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05054725 ↗	Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies	Recruiting	Amgen	Phase 2	2021-10-01	The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
NCT05054725 ↗	Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies	Recruiting	Sanofi	Phase 2	2021-10-01	The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
NCT05054725 ↗	Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies	Recruiting	Revolution Medicines, Inc.	Phase 2	2021-10-01	The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
NCT05251038 ↗	Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer	Not yet recruiting	Amgen	Phase 1/Phase 2	2022-05-01	This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line treatment. There will be a safety lead in to determine the safety and tolerability of the sotorasib in combination with standard chemotherapy. A Simon two-stage design will be employed to evaluate the efficacy of sotorasib in combination with standard of care second line chemotherapy.
NCT05251038 ↗	Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer	Not yet recruiting	Devalingam Mahalingam	Phase 1/Phase 2	2022-05-01	This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line treatment. There will be a safety lead in to determine the safety and tolerability of the sotorasib in combination with standard chemotherapy. A Simon two-stage design will be employed to evaluate the efficacy of sotorasib in combination with standard of care second line chemotherapy.

Clinical Trial Conditions for LUMAKRAS

Condition Name

Condition Name for LUMAKRAS
Intervention	Trials
Non-small Cell Lung Cancer	2
Advanced Malignant Solid Neoplasm	1
KRAS P.G12C	1
Metastatic Malignant Solid Neoplasm	1

Condition MeSH

Condition MeSH for LUMAKRAS
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	2
Lung Neoplasms	2
Neoplasms	1
Pancreatic Neoplasms	1

Clinical Trial Locations for LUMAKRAS

Trials by Country

Trials by Country for LUMAKRAS
Location	Trials
United States	7

Trials by US State

Trials by US State for LUMAKRAS
Location	Trials
Tennessee	1
Nebraska	1
New York	1
Maryland	1
Georgia	1

Clinical Trial Progress for LUMAKRAS

Clinical Trial Phase

Clinical Trial Phase for LUMAKRAS
Clinical Trial Phase	Trials
Phase 2	2
Phase 1/Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for LUMAKRAS
Clinical Trial Phase	Trials
Not yet recruiting	3
Recruiting	1

Clinical Trial Sponsors for LUMAKRAS

Sponsor Name

Sponsor Name for LUMAKRAS
Sponsor	Trials
Amgen	2
Sanofi	1
Revolution Medicines, Inc.	1

Sponsor Type

Sponsor Type for LUMAKRAS
Sponsor	Trials
Industry	5
Other	2
NIH	1